MinorAntiplatelet agents – P2Y12 receptor inhibitors×Sodium-glucose co-transporter 2 inhibitors (SGLT2i)
Updated · Methodology
Mechanism
In the liver, cytochrome P450 enzymes, mainly CYP2C19, convert clopidogrel to its active metabolite. Its glucuronide metabolite inhibits CYP2C8, so the SmPC asks for caution when clopidogrel is combined with drugs mainly cleared through CYP2C8, such as repaglinide (Plavix SmPC, European Medicines Agency, EMA). The main metabolic pathway of empagliflozin is glucuronidation by UGT2B7, UGT1A3, UGT1A8 and UGT1A9. The empagliflozin documents say nothing about a role for CYP2C8, and empagliflozin does not inhibit, inactivate or induce cytochrome P450 enzymes (empagliflozin SmPC, EMA). In clopidogrel clinical trials, patients also received antidiabetic drugs, including insulin, with no evidence of clinically relevant adverse interactions (Plavix SmPC, EMA).
Symptoms
The documents describe no symptoms linked to this combination. Each drug keeps its own adverse effects. Clopidogrel prolongs bleeding. Its adverse reactions of unknown frequency include insulin autoimmune syndrome, which can lead to severe hypoglycaemia (Plavix SmPC, European Medicines Agency, EMA). Empagliflozin can cause volume depletion with low blood pressure and complicated urinary tract infections. It can also cause ketoacidosis, including when blood glucose is only moderately raised, below 14 mmol/L (empagliflozin SmPC, EMA).
Management
According to the documents, the combination is acceptable, and the doses of clopidogrel and empagliflozin need no change. No document names the pair. In clopidogrel clinical trials, patients received antidiabetic drugs, including insulin, together with clopidogrel with no evidence of clinically relevant adverse interactions (Plavix SmPC, European Medicines Agency, EMA). Use clopidogrel with caution together with drugs mainly cleared through CYP2C8, such as repaglinide (Plavix SmPC, EMA, and Plavix label, US Food and Drug Administration, FDA). Empagliflozin is not one of them: its main metabolic pathway is glucuronidation by UGT enzymes (empagliflozin SmPC, EMA, and Jardiance label, FDA). Before elective surgery, stop clopidogrel 7 days in advance if its antiplatelet effect is not wanted during that time (Plavix SmPC, EMA). Interrupt empagliflozin, if possible, at least 3 days before surgery or procedures with prolonged fasting (Jardiance label, FDA). Also interrupt it in people hospitalised for major surgery or serious acute illness (empagliflozin SmPC, EMA). Assess renal function before starting empagliflozin and at least once a year after that (empagliflozin SmPC, EMA). Experience with clopidogrel in renal impairment is limited, so use it with caution (Plavix SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Ficha técnica Plavix 75 mg comprimidos recubiertos con película (clopidogrel) (2022)– AEMPS CIMA, ficha técnica Plavix 75 mg, nº registro 98069001 (EU/1/98/069), texto EMA, revisión diciembre 2022, secciones 4.2, 4.4 y 4.5
- FDA: Plavix (clopidogrel) prescribing information (2025)– FDA, DailyMed setid de8b0b67-eb25-4684-83b5-7ad785314227 (Sanofi-Aventis U.S.), revised 05/2025, Boxed Warning, sections 5.2, 6.1 (Table 1, CURE), 7.2, 7.4 and 7.7
- EMA: Ficha técnica: Empagliflozina (EU/1/14/930), sección 4.5 (2026)– EMA, Jardiance 10 mg comprimidos recubiertos con película (Boehringer Ingelheim International GmbH, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114930014, consultada 30.10.2026, sin fecha de revisión en CIMA, secciones 4.4, 4.5 y 5.2
- FDA: Jardiance (empagliflozin) prescribing information (2026)– FDA, DailyMed setid faf3dd6a-9cd0-39c2-0d2e-232cb3f67565 (Boehringer Ingelheim Pharmaceuticals), revisión 01/2026 (versión 31), secciones 2.3, 7 (Table 4) y 12.3